北方華創(002371.SZ):擬收購北廣科技旗下射頻應用技術相關資產
格隆匯3月18日丨北方華創(002371.SZ)公佈,公司全資子公司北京北方華創微電子裝備有限公司(“北方華創微電子”),擬以現金方式收購關聯方北京北廣科技股份有限公司(“北廣科技”)持有的射頻應用技術相關資產。此次交易的不含税交易價格為5921.77萬元,含税交易價格為6396.83萬元。
北方華創微電子是國內主流高端半導體裝備廠商,主要產品有刻蝕機、PVD(物理氣相沉積)、CVD(化學氣相沉積)等。射頻技術為公司多種半導體設備產品的核心技術。此次收購有利於提高北方華創微電子射頻應用技術水平,增強公司半導體裝備產品核心應用技術開發能力,有利於公司可持續發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.